Sanofi Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sanofi (Bridgewater, NJ): 66 reconciled FDA prescription therapies (1.7% 2025 to 2030 cliff risk), $4.79B 2024 CMS Part D & Medicaid spend, and 59 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBridgewater, NJ
Reconciled FDA Portfolio Therapies66
2025 to 2030 Patent-Cliff Revenue Exposure1.7%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$4.79B
2024 Medicare Part D Spend$3.53B
2024 Medicaid Spend$1.26B
California HCAI SB 17 Filings59 WAC filings (max 52.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.